US4407801A - Anti-ischemic pharmaceutic compositions - Google Patents

Anti-ischemic pharmaceutic compositions Download PDF

Info

Publication number
US4407801A
US4407801A US06/306,224 US30622481A US4407801A US 4407801 A US4407801 A US 4407801A US 30622481 A US30622481 A US 30622481A US 4407801 A US4407801 A US 4407801A
Authority
US
United States
Prior art keywords
trimethoxybenzyl
piperazine
day
patients
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/306,224
Other languages
English (en)
Inventor
Jean-Claude Arnaud
Michelle Devissaguet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Science Union et Cie
Original Assignee
Science Union et Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9246419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US4407801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Science Union et Cie filed Critical Science Union et Cie
Assigned to SCIENCE UNION ET CIE SURESNES 92150 14 RUE DU VAL D'OR, (FRANCE) reassignment SCIENCE UNION ET CIE SURESNES 92150 14 RUE DU VAL D'OR, (FRANCE) ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ARNAUD, JEAN-CLAUDE, DEVISSAGUET, MICHELLE
Application granted granted Critical
Publication of US4407801A publication Critical patent/US4407801A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • This invention relates to a method for treating ischaemia.
  • U.S. Pat. No. 3,262,852 described a novel vasodilative substance constituted by the dihydrochloride of 1-(2,3,4-trimethoxybenzyl)piperazine of the formula ##STR1## named trimetazidine dihyrochloride.
  • VASTAREL registered mark listed in the "Dictionnaire Vidal”. (O.V.P. Paris, France).
  • a disintegrating agent such as mannitol or sodium carboxymethyl starch
  • the addition salts there may be mentioned more especially the salts with a mineral acid, such as the hydrochloride,or the phosphate, or with an organic acid, such as the acetate, lactate, pyruvate, tartrate, citrate, maleate, fumarate, benzoate, 2,4-dichlorobenzoate, nicotinate, isonicotinate, benzenesulphonate, naphthalenesulphonate, p-toluenesulphonate, thiazole 5-carboxylate, methanesulphonate, ethanesulphonate, isethionate, glucose 1-phosphate or the glucose 1,6-diphosphate.
  • a mineral acid such as the hydrochloride,or the phosphate
  • an organic acid such as the acetate, lactate, pyruvate, tartrate, citrate, maleate, fumarate, benzoate, 2,4-dichlorobenzoate, nicotinate, isonicot
  • the addition salt is generally formed with two equivalents of a monovalent acid. It is, however, possible to form a salt with a single equivalent of a monovalent acid.
  • the dihydrochloride is mentioned more especially as the active principle of the pharmaceutical compositions according to the invention.
  • trimetazidine hydrochloride at dosages of from 6 to 12 mg daily, produced a vasodilative action owing to adrenolytic or noradrenolytic effects. This resulted in an action, having a peripheral origin, on the vessels of the general circulatory system, especially on the coronary vessels.
  • These compositions were therefore directed at patients suffering from arteritis, coronaritis, Raynaud's disease, nocturnal acroparasthesia or functional disorders of the veins.
  • the compositions used were sugar-coated tablets that dissolved slowly and contained 1% of active principle associated with scarcely soluble excipients.
  • excipients or inert vehicles for oral, parenteral or rectal use there may be mentioned, for the solid oral forms, calcium carbonate, tricalcium phosphate, magnesium phosphate, mixed silicates of magnesium, silica, titanium silicate, talc and magnesium stearate; for the liquid forms for drinking or injecting, water, sugar solutions, gum solutions and saline solutions; and for suppositories, cocoa butter or polyethylene glycol stearates.
  • galenic compositions having accelerated dissolution reinforced the effectiveness of that protective effect against the metabolic disorders caused by hypoxia; that effect was unexpected since metabolic disorders develop over several hours or even several days and the composition showed itself more active with a dissolution beginning from one to two minutes after ingestion.
  • the long-term consequence is the death of the cell.
  • compositions according to the invention restore the energy activity of the cell exposed to ischaemia, maintain an intracellular level of adenosine triphosphoric acid comparable to that of the cell when functioning normally, permit the ionic pump of the membrane to function well and preserve the cross-membrane gradients of sodium and potassium. This maintenance of the cell homeostasis is shown at the haemodynamic level by a reduction in the work of the ischaemic myocardium.
  • compositions according to the invention therefore find use in:
  • ophthalmology in the treatment of chorio-retinal disorders of ischaemic origin (angiosclerosis, retinal ischaemia, degeneration of the macula),
  • otology in the treatment of cochleovestibular disorders (vertigo, Meniere's disease, tinnitus).
  • compositions according to the invention contain 20 or 40 mg of the addition salt of 1-(2,3,4-trimethoxybenzyl)piperazine together with an excipient or an inert vehicle.
  • composition is made in the form of film-coated tablets having a water-soluble coating that is approximately 1/10 mm thick, the active principle being concentrated to 20%.
  • the rapidly soluble excipients there may be mentioned mannitol.
  • the daily dosage is within the range of from 20 to 80 mg of active principle, divided into from 1 to 3 equal administrations.
  • the coating film is very fine and the whole constitutes a small tablet.
  • composition according to Example 1 has an immediate action having a metabolic effect.
  • the dissolution time of the active principle is from 2 to 7 minutes for a dissolution of 50%, and from 15 minutes for a rate of dissolution greater than 95%.
  • the sodium carboxymethyl starch added to the trimetazidine dihydrochloride permits a rapid disintegration of this latter constituent of the composition of Example 2: the disintegration time is from one minute; there is a physical "explosion" of the compound.
  • the other products serve to facilitate the formation into tablets in the press bringing about the direct compression.
  • compositions according to the invention have a certain number of pharmacological properties which all converge on the correction of the effects on the tissue of ischaemia.
  • compositions according to the invention considerably and significantly increase the survival time of the myocardium by delaying the appearance of irreversible ischaemic lesions.
  • the technique used is that recommended by Thomasset. It consists in measuring the survival time of an organ by measuring its impedance, which reflects the ionic exchanges through the membrane.
  • the impedance of the isolated heart of a dog placed in a survival liquid was evaluated. When the hearts came from untreated animals, the average survival time was 32 minutes. When the animals had been treated previously with a dosage of 2.5 mg/kg administered intravenously before the organ was removed, the survival time increased to 49 minutes.
  • That increase in the survival time is caused by a slowing down of the cross-membrane ionic exchanges of sodium and potassium responsible for the appearance of an intracellular oedema, warning sign of the death of an organ.
  • compositions according to the invention correct the disturbances of the cellular metabolism of energy.
  • compositions according to the invention restore the energy potential of the myocardial cell.
  • vasopressin induces a breakdown of the adenosine triphosphoric acid content, a form of energy storage.
  • the effects of vasopressin are eliminated.
  • the adenosine triphosphoric acid concentrations return to a level identical to that found in the controls.
  • compositions according to the invention combat the disturbances of the electro-encephalographic trace related to cerebral ischaemia.
  • Cerebral ischaemia can be brought about in rabbits by clamping the arterial vessels at their aortic origin. This causes the appearance of an electrical silence.
  • compositions according to the invention To verify the anti-ischaemic effects of the compositions according to the invention, solutions of 1-(2,3,4-trimethoxybenzyl)piperazine at dosages corresponding to 0.625 and 1.25 mg/kg were injected intravenously into groups of rabbits immediately before the clamping.
  • the compositions according to the invention were injected intravenously into groups of rabbits immediately before the clamping.
  • compositions according to the invention combat all ischaemic conditions of the chorio-retinal cells.
  • the placebo and the different dosages of the (trimethoxybenzyl)piperazine were administered in identical manner, at the rate of three doses daily.
  • the (trimethoxybenzyl)piperazine tablets and the placebo tablets were identical and could not be distinguished by the patient.
  • the population studied comprised 27 patients aged from 43 to 79 years with an average age of 60 years, of which 25 were men aged from 43 to 79 years with an average age of 60 years and 2 were women of 56 and 65 years.
  • this action was at a maximum at the dosage of 40 mg/24 hours (P ⁇ *0.001) in a highly significant manner, without the appearance of a significant difference between 40 and 60 mg/24 hours.
  • compositions according to the invention in comparison with a placebo, are shown by a positive effort test (anginal pain and under-displacement, caused by lesions, of the S-T superior or equal to 1.5 mV), the compositions according to the invention, in comparison with a placebo, are shown by a positive effort test (anginal pain and under-displacement, caused by lesions, of the S-T superior or equal to 1.5 mV), the compositions according to the invention, in comparison with a placebo, are
  • the dosage of 10 mg of the (trimethoxybenzyl)piperazine daily has an insufficient therapeutic activity (the activity did not reach a degree of statistical significance),
  • the therapeutic activity is at a maximum in a highly significant manner (P ⁇ 0.001), with a satisfactory tolerance.
  • the aim of the following study was to demonstrate the activity of the (trimethoxybenzyl)piperazine in the form of tablets of 20 mg on structures especially sensitive to ischaemia--the retina and the papilla.
  • Treatment using the compositions according to the invention was started within a period dating from the day of diagnosis itself to 2 weeks after diagnosis.
  • the treatment was the (trimethoxybenzyl)piperazine, in injectable form, each ampoule containing 20 mg, at a dosage of one or two ampoules daily, that is to say from 20 to 40 mg, for from 7 to 10 days by continuous perfusion or direct intravenous injection and prescribed as the only therapy.
  • the average length of treatment was 9 days.
  • peripheral visual field (kinetic) with Goldmann apparatus
  • Angiofluorography showed a morphological appearance that had virtually returned to normal in 8 cases out of 9; furthermore, the retinal circulation time improved in 3 cases out of 5.
  • the (trimethoxybenzyl)piperazine is a novel anti-ischaemic therapy having an original mode of action. In fact, it is aimed at directly protecting the cell from the consequences of ischaemia by controlling the cellular cross-membrane ionic flows which are disturbed in the course of ischaemia.
  • a double blind study was carried out in order to verify the results obtained in a previous study on two indications, Meniere's vertigo and vascular vertigo, by comparing the effectiveness of the (trimethoxybenzyl) piperazine at 20 mg with that of a major product as reference, the activity of which product on symptoms of vertigo is recognised.
  • the dosage was two tablets daily for 3 months.
  • the treatment considered as a basal treatment consisted of prescribing, without any associated therapy, (trimethoxybenzyl)piperazine at a rate of 40 mg/day, or the reference product at a rate of 24 mg/day, in 2 daily doses for 3 months.
  • the distribution of the two products was done by drawing lots for each of the two indications involved.
  • the units of treatment were given to the patient according to his order of entry into the study.
  • Clinical and para-clinical criteria based on the symptoms presented made it possible firstly to assess the condition of the patients before treatment and, in the same manner, to compare the pathological condition of the two therapeutic groups in order to verify the intrinsic activity of the (trimethoxybenzyl)piperazine at 20 mg, and of the reference product, and then to compare the results obtained with the one and the other product.
  • vestibular examinations Barany's caloric test and pendular tests using electronystagmographic recording.
  • tinnitus The intensity, frequency and length were rated using a score of seriousness of from 3: very intense disorder, to 0: absence or disappearance of the disorder.
  • the two therapeutic groups were revealed to be comparable with regard to their population (number of patients, age, sex), the diagnosis made (equal number of Meniere's vertigo and vascular vertigo in each group), the duration of the disorders (from 6 months to 5 years) and the symptoms presented.
  • the vestibular tests showed a return to normal, or gave a better response or a better trace, in the caloric test in 69% of the cases, and in 74% of the cases in the pendular test with electronystagmography.
  • the audiometric curve improved from 5 to 10 dB in 37% of the cases.
  • the aim of the controlled double blind crossover study was to evaluate the therapeutic interest of the compositions according to the invention compared with a major anti-anginal medicament, perhexiline maleate, as reference.
  • each group the treatment lasted one month, from the end of the first to the end of the second month after the infarct, and was administered at a rate of 40 mg/day of the (trimethoxybenzyl)piperazine in tablets of 20 mg and 400 mg/day of perhexiline maleate in two daily doses taken at mealtimes.
  • the second and third effort tests(T2 and T3) carried out at the middle and end of the treatment (on the 45th and 60th day after the infarct) respectively, were continued until a cardiac frequency equal to the maximum theoretical frequency was obtained, except when the patient stopped earlier owing to exhaustion, ischaemic disorders and maladjustment to effort.
  • the coronary reserve may be defined as being the threshold of appearance of an under-displacement of the S-T segment during effort, and is expressed either as a percentage of the maximum theoretical frequency (MTF) or as a function of the systolic tension time or STT (product of the systolic arterial blood pressure multiplied by the cardiac frequency) which is itself parallel to the oxygen consumption.
  • MTF maximum theoretical frequency
  • STT product of the systolic arterial blood pressure multiplied by the cardiac frequency
  • the subjects involved were those whose electrical trace was modified at T1, in other words those whose coronary reserve was ⁇ 70% of the MTF before treatment. The sample was therefore restricted to the most seriously ill patients.
  • the improvement in the coronary reserve is 19% at the second test(T2) and 22% at the third test(T3). Taking into account the uncertainties related to the determination of the STT, the increase of the latter is not significant, but it agrees with the significant improvement in the coronary reserve expressed as a percentage of the maximum theoretical frequency.
  • the number of observations retained after having removed the patients unable to provide an effort of 80 watts in the first test was 12 between T1 and T2 and 11 between T1 and T3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US06/306,224 1980-09-30 1981-09-28 Anti-ischemic pharmaceutic compositions Expired - Lifetime US4407801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8020919 1980-09-30
FR8020919A FR2490963B1 (fr) 1980-09-30 1980-09-30 Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine

Publications (1)

Publication Number Publication Date
US4407801A true US4407801A (en) 1983-10-04

Family

ID=9246419

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/306,224 Expired - Lifetime US4407801A (en) 1980-09-30 1981-09-28 Anti-ischemic pharmaceutic compositions

Country Status (14)

Country Link
US (1) US4407801A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU550761B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE890568A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1169775A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH650675A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3139005A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2490963B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2084019B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR75803B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE51764B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1171557B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU83654A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ198435A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA816766B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000812A1 (en) * 1984-07-30 1986-02-13 Pharmacia Ab A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof
US20080004284A1 (en) * 2006-04-10 2008-01-03 Rahman Ahmad H Method for treating fibromyalgia syndrome and related conditions
EA009776B1 (ru) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав
CZ299461B6 (cs) * 1999-12-17 2008-08-06 Les Laboratoires Servier Matricová tableta umožnující prodloužené uvolnování trimetazidinu po orálním podání
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
CN105055352A (zh) * 2015-08-11 2015-11-18 瑞阳制药有限公司 盐酸曲美他嗪片及其制备方法
CN107982231B (zh) * 2018-01-03 2021-05-07 江苏吴中医药集团有限公司 一种盐酸曲美他嗪片及其制备方法
US11123345B2 (en) * 2016-11-21 2021-09-21 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448776A (en) * 1981-02-12 1984-05-15 Karl Bucher Method of using certain substituted aliphatic secondary amines or their salts for easing breathing
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
EP1104673A1 (en) * 1999-11-30 2001-06-06 Bayer Classics A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition
FR2805463B1 (fr) * 2000-02-25 2003-01-24 Adir UTILISATION DE LA TRIMETAZIDINE POUR L'OBTENTION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES A INHIBER L'ACYL-CoA ACETYLTRANSFERASE
FR2818549B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controlee de trimetazidine
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262852A (en) * 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR805M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1960-06-30 1961-09-01

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262852A (en) * 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Brodbin, P. et al., Brit. J. Clin. Pract., 22(9), 395 (1968). *
Mehrotra, T. et al., Brit. J. Clin. Pract., 21(11), 553 (1967). *
Saito, D., Japan Circ. J., 40, 363, (1976). *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000812A1 (en) * 1984-07-30 1986-02-13 Pharmacia Ab A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof
CZ299461B6 (cs) * 1999-12-17 2008-08-06 Les Laboratoires Servier Matricová tableta umožnující prodloužené uvolnování trimetazidinu po orálním podání
US20080004284A1 (en) * 2006-04-10 2008-01-03 Rahman Ahmad H Method for treating fibromyalgia syndrome and related conditions
EA009776B1 (ru) * 2006-07-18 2008-04-28 Мераб Ревазович Кокеладзе Способ изготовления таблетированной лекарственной формы триметазидина дигидрохлорида и ее состав
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders
CN105055352A (zh) * 2015-08-11 2015-11-18 瑞阳制药有限公司 盐酸曲美他嗪片及其制备方法
US11123345B2 (en) * 2016-11-21 2021-09-21 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
US11986473B2 (en) 2016-11-21 2024-05-21 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
CN107982231B (zh) * 2018-01-03 2021-05-07 江苏吴中医药集团有限公司 一种盐酸曲美他嗪片及其制备方法

Also Published As

Publication number Publication date
GB2084019B (en) 1984-09-12
ZA816766B (en) 1982-09-29
AU550761B2 (en) 1986-04-10
GR75803B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-08-02
IE812256L (en) 1982-03-30
IT8149377A0 (it) 1981-09-28
FR2490963A1 (fr) 1982-04-02
DE3139005A1 (de) 1982-05-06
LU83654A1 (fr) 1982-04-14
IT1171557B (it) 1987-06-10
AU7574481A (en) 1982-04-08
CA1169775A (fr) 1984-06-26
CH650675A5 (fr) 1985-08-15
NZ198435A (en) 1984-02-03
GB2084019A (en) 1982-04-07
FR2490963B1 (fr) 1986-04-18
BE890568A (fr) 1982-03-30
IE51764B1 (en) 1987-03-18

Similar Documents

Publication Publication Date Title
US5510101A (en) Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US4981871A (en) Treatment of ocular hypertension with class I calcium channel blocking agents
US4407801A (en) Anti-ischemic pharmaceutic compositions
GAY et al. Topical guanethidine therapy for endocrine lid retraction
DE69934305T2 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
Schoenfeld et al. Retinal hemorrhages in the newborn following labor induced by oxytocin or dinoprostone
US6462066B2 (en) Method and composition for treatment of ischemic neuronal reperfusion injury
HU213272B (en) Process for producing pharmaceutical composition containing sorbitol for topical treating enhanced intraocular tension
Hoagland et al. Antihistaminic drugs for colds: evaluation based on a controlled study
WO1993014757A1 (en) Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol
JP2610619B2 (ja) 高眼圧症治療用点眼剤
SEEGER et al. Ophthalmological use of mannitol
US5252607A (en) Treatment of low pressure glaucoma and ischemic retinal degeneration
KR100854058B1 (ko) 스테로이드를 유효 성분으로 하는 망맥락막 질환 치료제
RU2303449C1 (ru) Способ лечения отечной формы диабетической макулоретинопатии
RU2585400C2 (ru) Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола
JP2004331502A (ja) 視神経細胞保護剤
RU2481124C1 (ru) Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
Bietti et al. Propylenglycol a new osmotic agent for ophthalmic uses
Keith Intravenous urea in glaucoma
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
US20030225101A1 (en) Method of treating retinal occlusion with sildenafil
JP3530542B2 (ja) 眼科用アルガトロバン製剤
Moore 8 Chapter Anticholinergic Agents (Parasympatholytics)
Sampaolesi et al. Medical Therapy in Glaucoma

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCIENCE UNION ET CIE SURESNES 92150 14 RUE DU VAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:ARNAUD, JEAN-CLAUDE;DEVISSAGUET, MICHELLE;REEL/FRAME:003941/0043

Effective date: 19810825

Owner name: SCIENCE UNION ET CIE SURESNES 92150 14 RUE DU VAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARNAUD, JEAN-CLAUDE;DEVISSAGUET, MICHELLE;REEL/FRAME:003941/0043

Effective date: 19810825

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYMENT IS IN EXCESS OF AMOUNT REQUIRED. REFUND SCHEDULED (ORIGINAL EVENT CODE: F169); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

REFU Refund

Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: R171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M185); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12